Potential risks of biosafety and prevention strategies in medical and pharmaceutical research laboratories
Author:
Affiliation:

Institute of Materia Medica Chinese Academy of Medical Science,Equipment Purchase Department

  • Article
  • | |
  • Metrics
  • |
  • Reference [22]
  • | | | |
  • Comments
    Abstract:

    Medical and pharmaceutical research laboratory usually involves wide range of study aspects. The materials used in the laboratory are various, including animals, microorganisms and nano-particles and other kinds. Meanwhile, with the production of more and more waste, more biosafety risks would be created. Here, we outlined the potential safety risks related with gene amplification, gene recombination, pathogenic microorganism research, nanotechnology, animal experiments, genetically altered animals, and experimental waste, etc. It also proposed preventive measures for laboratory biosafety risks, which mainly associate with developing strict legal frameworks, bettering hardware infrastructure, strengthening safety awareness, and enhancing education and training programs.

    Reference
    [1] 林梅芬,周明施,周晔,等. 温州市基因扩增实验室生物安全风险评估 [J]. 中国公共卫生管理,2023,39(4) : 580-586.Lin MF, Zhou MS, Zhou Y, et al. Biosafety risk assessment analysis of gene amplification laboratory in Wenzhou City [J]. Chinese Journal of Public Health Management, 2023, 39(4): 580-586.
    [2] BergP, Baltimore D, Boyer H W, et al. Potential biohazards of recombinant DNA molecules [J]. Rroc Nat Acad Sci USA,1974,(7):2593-2594.
    [3] Hug K. Genetically modified organisms:do the benefits outweigh the risks? [J]. Medicina (Kaunas),2008,44(2):87-99.
    [4] 左锟澜,邹诗施,吴宗震,等. 病原体相关合成生物学的生物安全风险和应对策略研究[J]. 中国生物工程杂志, 2023, 43(9): 120-130.Zuo KL, Zou SS, Wu ZZ, et al. Biosafety Risks and Countermeasures of Pathogen Related Synthetic Biology [J]. China biotechnology, 2023, 43(9): 120-130.
    [5] 蔡启良,蔡霞,瞿涤,等.我国高等级生物安全实验室现状、发展和挑战 [J]. 国家安全研究,2023,(1):61-76.Cai QL, Cai X, Zhai D, et al. The Status Quo of and Development Challenges Facing China''s High-Level Biosafety Labs [J]. China security studies, 2023, (1): 61-76.
    [6] Rosano G L,Morales E S,Ceccarelli E A. New tools for recombinant protein production in Escherichia coli: a 5?year update [J]. Protein Science,2019,28(8): 1412-1422.
    [7] Smolskaya S,Logashina Y A, Andreev Y A. Escherichia coli extract-based cell-free expression system as an alternative for difficult?to?obtain protein biosynthesis [J]. International Journal of Molecular Sciences,2020,21(3): 928.
    [8] 宁峻涛,邹诗施,左锟澜,等. 合成生物活性物质的生物安全风险和应对策略研究 [J]. 中国生物工程杂志,2023,43(2): 180-189.Ning JT, Zou SS, Zuo KL, et al. Biosafety Risks and Countermeasures of Active Substance in Synthesis Biology[J]. China biotechnology, 2023, 43(2): 180-189.
    [9] Steinmetz M,Richter R. Plasmids designed to alter the antibiotic resistance expressed by insertion mutations in Bacillus subtilis,through in vivo recombination [J]. Gene,1994,142(1): 79-83.
    [10] Nielsen J. Yeast systems biology: model organism and cell factory [J]. Biotechnology Journal, 2019,14(9): e1800421.
    [11] Anoop V,Rotaru S,Shwed P S,et al. Review of current methods for characterizing virulence and pathogenicity potential of industrial Saccharomyces cerevisiae strains towards humans [J]. FEMS Yeast Research,2015,15(6): fov057.
    [12] 付萌萌,苏丹丹,左锟澜,等. 人体免疫相关的合成生物学生物安全风险和应对策略研究 [J]. 中国生物工程杂志,2023,43(6): 125-132.Fu MM, Su DD, Zuo KL, et al. Biosafety risks of Synthetic Biology related to Human Immunity and the Countermeaseures [J]. China Biotechnology, 2023, 43(6): 125-132.
    [13] Venkatesan S,Rosenthal R,Kanu N,et al. Perspective: APOBEC mutagenesis in drug resistance and immune escape in HIV and cancer evolution [J]. Annals of Oncology,2018,29(3): 563-572.
    [14] Herwaldt BL. Laboratory-acquired parasitic infections from ac- cidental exposures [J]. Clin Microbiol Rev,2001,14(4):659- 688.
    [15] Renwick L C,Brown D,Clouter A,et al. Increased inflammation and altered macrophage chemotactic response caused by two ultrafine particle types [J]. Occup Environ Med,2004,61:442-447.
    [16] Nemmar A,Hoylaerts M F,Hoet P H M, et al.Size effects of intratracheally instilled particles on pulmonary inflammation and vascular thrombosis [J]. Toxicol Appl Pharmacol,2003,186:38-45.
    [17] Peters A,Dockery D W,Muller J E, et al. Increased particulate air pollution and the triggering of myocardial infarction [J]. Circ,2001,103 :2810.
    [18] Gole D R,Litonjua A,Schwartz J, et al. Ambient pollution and heart rate variability [J].Circ,2000,101: 1267-1273.
    [19] 刘丽艳,韩艳梅,李文超,等.实验动物潜在生物安全威胁及降低风险的建议 [J]. 实验技术与管理, 2020, 37(2): 264-266.Liu LY, Han YM, Li WC, et al. Potential biosafety threats of laboratory animals and suggestions for risk reduction [J]. Experimental Technology and Management, 2020, 37(2):264-266.
    [20] Ryoji I,Takeshi T,Mamoru I. Humanized mouse models:Application to human diseases [J]. Journal of Cellular Physiology,2018,233(5) :2723-2728.
    [21] Sun J,Zhuang Z ,Zheng J ,et al. Generation of a broadly useful model for COVID-19 pathogenesis, vaccination and treatment [J]. Cell,2020,182(3):734-743.
    [22] 栾一飞,杨悦,刘英奎,等. 中美高校生物学实验室准入安全培训工作比较 [J]. 中国高等医学教育,2021(2):129-130.Luan YF, Yang Y, Liu YK, et al. Comparison of safety training for admission to biology laboratories in Chinese and American universities [J]. Chinese Higher Medical Education, 2021(2):129-130.
    Related
    Cited by
Get Citation
Related Videos

Share
Article Metrics
  • Abstract:
  • PDF:
  • HTML:
  • Cited by:
History
  • Received:March 18,2024
  • Revised:March 23,2024
  • Adopted:April 12,2024
Article QR Code